3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Carboplatin
7
Paclitaxel
4
Cisplatin
4
pembrolizumab
3
Pemetrexed
3
zipalertinib
2
selpercatinib
2
durvalumab
2
Nivolumab
2
Blood Specimen Collection
2
zimberelimab
1
taletrectinib
1
sotorasib
1
sacituzumab govitecan
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
cemiplimab
1
atezolizumab
1
alectinib
1
Tomography, Emission-Computed, Single-Photon
1
Toll-Like Receptor 1
1
Telescopes
1
Surveys and Questionnaires
1
Radiosurgery
1
One-Lung Ventilation
1
Omacor
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Health Records, Personal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
1 year
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled